Get Up To Date Event Information

Join our priority contact list and receive the latest event news.

Keynote Presentations

Clinical Development of Mipomersen, an Antisense Second-Generation Oligonucleotide Targeting Apolipoprotein B
Tejdip Singh, M.D., Medical Director, Global Patient Safety and Risk Management, Genzyme Corporation, USA

Oligonucleotide and Delivery Platform Optimization Strategies for siRNA Drug Development

Laura Sepp-Lorenzino, Ph.D., Senior Director, RNA Therapeutics, Merck & Co., Inc., USA

Recent Advances in Routes of Delivery for Peptide Pharmaceuticals

Nozer Mehta, Ph.D., Vice President, R&D, UniGene Laboratories, Inc., USA

Overview of Peptide Therapeutics and Vaccines in Development

Yuji Heike, M.D., Ph.D., Chief of Medical Staff, Department of Medical Oncology, National Cancer Center Hospital, Japan

Evolution and Development of GLP-1 Based Therapeutics

Andrew A. Young, M.D., Ph.D., Vice President, Head, Enterendocrine Biology, GlaxoSmithKline, USA

A Pivotal Year for Oligonucleotide Therapeutics

Arthur A. Levin, Ph.D., Chief Development Officer, Santaris A/S, USA and Denmark

RaPID Selection of a New Class of Peptide Drug Leads against Various Therapeutic Targets

Hiroaki Suga, Ph.D., Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan

Conference Language

The conference will be conducted in English without translation.

The best forum to gain applied and basic knowledge, build your collaborative network, and learn skills to move your projects forward in one of today's hottest research areas

AsiaTIDES continues to be the premier forum to get a comprehensive update, meet key players and increase your knowledge of the oligonucleotide- and peptide-based therapeutics fields.

The faculty list for the 2012 program is the strongest yet, with more representation from big pharma than ever before. Hear new data and strategic perspectives from Merck, Genzyme, and GlaxoSmithKline, including three presentations from Glaxo on a peptide project and their assessments of both the oligo and peptide landscape. Plus hear from Isis, Novo Nordisk, Ipsen, Quark, Alnylam, Santaris, Tekmira and a host of other important companies you need to follow to stay abreast of this field.

"My first time attending AsiaTIDES was very enjoyable. AsiaTIDES brought my company meaningful information widely. I was very happy meeting the delegates from American/Europe, and Asian companies… The balance was good in oligonucleotide and peptide. I enjoyed conference hopping." - Dr. Yoshitsugu Akiyama, Senior Research Scientist, NOF Corporation, Japan

• Regulatory Updates: Preclinical Safety Assessment of Oligonucleotides and Peptides including Reports from JPMA and the Oligonucleotide Safety Working Group on ICH S6 and Off Target Effects
• miRNA, Oligonucleotides, Peptides and Peptide Vaccines: Updates on therapeutic candidates in preclinical and clinical development
• Manufacturing and analytical development strategies to speed process development
• Formulation and delivery updates to help you gauge product marketability

In-Depth Tutorials to Increase your Knowledge:

• Technical and Regulatory Aspects of Peptide Specifications and Characterization: From Preclinical through to Market Application
• Strategies and Approaches for in vivo Delivery of Oligonucleotides

Past attendees congratulate AsiaTIDES